ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 241 entries already.
Fifty years after the invention of hybridoma technology, biologics have become a cornerstone of oncology drug discovery and development. From the first monoclonal antibody approval in 1995 to today’s complex antibody formats and cell-based therapies, biologics are reshaping cancer drug discovery. Yet, despite remarkable progress, the urgent need for novel targets that can exploit recent technological developments remains high.
T3 Pharmaceuticals shows how a biotech can move from first experiments to a major international deal keeping pace – and roots – in the Basel Area. The team built, tested and scaled inside Switzerland Innovation Park Basel Area’s Main Campus. Flexible private labs, certified shared facilities and an on-site expert community cut friction at every step. The result: faster iteration, smarter use of capital and a clear path from seed to global relevance — all inside Europe’s densest life sciences cluster.
Essential areas such as study planning, interpretation, regulatory guidance, and key study design decisions remain human responsibilities, although AI increasingly supports routine tasks. X-act gets involved after the preclinical phase supporting clients in all clinical research phases from Phase I to IV and beyond. Their service ranges from initial planning to final analysis, reporting, and regulatory submission. European Biotechnology spoke with Jasmin Atarodi, Managing Director of X-act Cologne Clinical Research GmbH, about the benefits of partnering with experienced data specialists.
The Celonic Group and CARBOGEN AMCIS AG have formed a strategic alliance to offer a fully integrated Antibody Drug Conjugate (ADC) development and manufacturing platform. This partnership combines Celonic’s biologics expertise with CARBOGEN AMCIS’s payload synthesis and conjugation capabilities, creating a seamless, end-to-end solution for ADC developers.
This year, BIO-Europe, Europe’s leading partnering event for the entire biotech ecosystem, will take place in Vienna. From 3 to 5 November, the industry’s most important decision-makers will meet here to negotiate partnerships, contracts and financing, and to learn about the latest developments and trends. With over 5,700 participants from 60 countries, 2025 is set to see a record number of delegates, sponsors, exhibitors and presenting companies.
Safeguarding temperature-sensitive materials is critical, and Ultra-Low Freezers (ULTs) ensure sample integrity at very low temperatures. Today’s customers demand not just reliability, but also sustainability under intensive use. The new U701V from B Medical Systems, with variable-speed technology, delivers the perfect balance: uncompromised performance, reliability, and sustainability.
New developments under the current U.S. administration may be a challenge for the pharma/biotech industry: the Inflation Reduction Act, Orange Book Challenges, Most Favored Nation Policy, and the new Trump-Lutnick Patent Tax. And it will likely affect European pharma and biotech.
After two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success.
The global biologics industry is entering a new phase of maturity. As costs tighten and timelines accelerate, CDMOs must deliver uncompromised quality while driving efficiency. Rezon Bio, an EU-based biologics CDMO with state-of-the-art facilities and a client-centric approach, was established to meet biotech and pharmaceutical client needs with agility, pragmatism, and trust.
FairJourney Biologics (Porto, PT) has appointed Dr Werner Lanthaler, long-standing Evotec CEO, as Chief Executive Officer. Founder António Parada will focus on innovation strategy on the Supervisory Board.